SecBot SecBot
DEFA14A ·Filed Aug 25, 2026

TBPH

Theravance Biopharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001104659-26-100863
Proxy solicitation materials
Actionable Insight • Neutral

The CYPRESS study missed its primary endpoint, but post-hoc analyses and a forthcoming FDA Type C meeting provide a potential, albeit uncertain, path forward for ampreloxetine. The stock's reaction will likely hinge on the outcome of the Type C meeting and the progress of the Zymeworks merger. Monitor for updates on the Type C meeting and any definitive proxy statement filings regarding the merger.

DirectionNeutral
Confidencemedium
Horizonmonths

ampreloxetine

▼ Bearish Named in this DEFA14A
Impact
Phase
Phase 3 (failed)
Time to market
Not applicable. The drug failed all Phase 3 trials and development has been terminated.
Next catalyst
None dated

What to watchAmpreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+20
Entry
$17.03
T+0 close · Aug 25, 2026 · via day close
Latest settled
0.00%
T+20 · $17.03
Vs SPY
−0.23%
α at T+20
Next horizon
T+60
in 2d
  1. T+0 · Aug 26 $17.03entry
  2. T+1 · 3mo ago +0.06%α −0.60% · $17.04
  3. T+5 · 3mo ago +0.23%α +0.35% · $17.07
  4. T+20 · 8w ago 0.00%α −0.23% · $17.03
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theravance Biopharma filed a DEFA14A (additional definitive proxy soliciting material) on August 25, 2026, making available a presentation on the Phase 3 CYPRESS study of ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA). The study missed its primary endpoint, but post-hoc analyses suggest a potential treatment effect, and the FDA has granted a Type C meeting to discuss a future study design. This filing is part of ongoing solicitation materials related to the proposed merger with Zymeworks Inc., previously announced on June 29, 2026.

Key Financial Metrics

Vote
merger approval

Key Facts

  • The primary endpoint of the Phase 3 CYPRESS study (change in OHSA composite score at week 8) was not statistically significant.
  • Post-hoc analyses in a 'Confirmed Symptomatic nOH' population showed statistically significant average treatment effects for OHSA, OHDAS, and OHQ scores.
  • The FDA has granted a Type C meeting request to align on the design of a future clinical study for ampreloxetine.
  • The filing is a DEFA14A, which is additional definitive proxy soliciting material related to the proposed merger with Zymeworks Inc., announced June 29, 2026.
  • The presentation includes data showing ampreloxetine was generally well tolerated with no signal of worsening supine hypertension.

Financial Impact

No financial figures reported in the filing. The filing relates to clinical data and regulatory interactions for ampreloxetine, and a proposed merger with Zymeworks Inc.

Risk Factors

  • The primary endpoint of the CYPRESS study was not met, indicating a failed trial.
  • Post-hoc analyses may not be replicated or predict clinical benefit in a future trial.
  • The FDA may reject a proposed study design or require additional trials, delaying or preventing approval.
  • The proposed merger with Zymeworks Inc. is subject to shareholder approval and other conditions, which may not be satisfied.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-100863
Document: 0001104659-26-100863-index.html0001104659-26-100863
Document: 0001104659-26-100863.txt0001104659-26-100863

Track record

12 reports on TBPH

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
  2. Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
  3. Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
  4. Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
  5. Aug 25, 202611w ago DEFA14A Neutral 4/10 Viewing Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
  6. Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
  7. Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
  8. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
  10. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026